Company to host a conference call tomorrow, March 7, 2024, at 10 A.M. EST
DALLAS–(BUSINESS WIRE)– Enhabit, Inc. (NYSE: EHAB), a leading home health and hospice care provider, today reported its results of operations for the fourth quarter ended December 31, 2023.
“Persistent focus on our Company’s strategies drove our positive fourth quarter results,” said Enhabit’s President and Chief Executive Officer Barb Jacobsmeyer. “Payor innovation success, including the finalization of another new national contract, continued success with our people strategy and strong performance in our quality outcomes are but a few of our high points for the end of 2023 and our start to 2024. We are excited about our future and our ability to meet the growing demand for home health and hospice services.”
SUMMARY PERFORMANCE – CONSOLIDATED
- Net service revenue of $260.6 million
- Net loss attributable to Enhabit, Inc. of $6.4 million
- Adjusted EBITDA of $25.2 million
- Loss per share of $0.13
- Adjusted earnings per share of $0.06
RECENT COMPANY HIGHLIGHTS
- Strong growth in home health Medicare Advantage admissions with non-episodic admissions up 34.2% driving total admission growth of 3.9% year over year
- Continued payor innovation progress with 11 new Medicare Advantage agreements negotiated during the fourth quarter
- Added one new national advanced episodic agreement effective January 1, 2024
- 25% of non-episodic visits now in payor innovation contracts at improved rates
- Home health cost per visit flat year over year
- 30-day hospitalization readmission rate in home health 20.5% better than national average
- Sequential growth in hospice average daily census
- Hospice cost per day decreased to $76 after stabilizing at $77 for the prior three quarters
- 53.2% better than the national average for hospice patient visits in the last days of life
- Continued success in recruitment and retention with a 21.5% increase in full-time nursing candidate pool year over year resulting in 119 net new full-time home health nursing hires in the fourth quarter
- Opened one home health and one hospice de novo location in the fourth quarter
FINANCIAL RESULTS
Consolidated
![Enhabit Reports Fourth Quarter Results and Issues Full-Year 2024 Guidance (1) Enhabit Reports Fourth Quarter Results and Issues Full-Year 2024 Guidance (1)](https://i0.wp.com/www.ehab.com/wp-content/uploads/2024/03/Screenshot-2024-03-06-at-3.26.07-PM-1024x562.png)
The continued shift to more non-episodic admissions in home health impacted consolidated revenue and Adjusted EBITDA by approximately $8 million, net of the impact from improved pricing of payor innovation contracts.
SEGMENT RESULTS
Home Health
![Enhabit Reports Fourth Quarter Results and Issues Full-Year 2024 Guidance (2) Enhabit Reports Fourth Quarter Results and Issues Full-Year 2024 Guidance (2)](https://i0.wp.com/www.ehab.com/wp-content/uploads/2024/03/Screenshot-2024-03-06-at-3.27.16-PM-1024x763.png)
The year-over-year decrease in revenue and Adjusted EBITDA was due primarily to the continued payor mix shift to more non-episodic admissions (approximately $8 million).
Non-episodic admissions grew 34.2% in the quarter, driving total admission growth of 3.9% year over year. Revenue per episode decreased year over year primarily due to patient mix. Cost per visit remained flat year over year as the reduction in nursing contract labor offset the impact of merit and market increases.
Hospice
![Enhabit Reports Fourth Quarter Results and Issues Full-Year 2024 Guidance (3) Enhabit Reports Fourth Quarter Results and Issues Full-Year 2024 Guidance (3)](https://i0.wp.com/www.ehab.com/wp-content/uploads/2024/03/Screenshot-2024-03-06-at-3.29.31-PM-1024x496.png)
Net service revenue increased year over year primarily due to an increase in revenue per day. Revenue per day increased primarily due to changes in our estimated recoverability of net service revenue and increased Medicare reimbursem*nt rates.
Adjusted EBITDA increased year over year primarily due to increased revenue per day and a reduction in general and administrative expenses. Cost per day increased year over year primarily due to increased labor costs resulting from the implementation of the new case management staffing model, including costs associated with dedicated on-call and triage nurses. General and administrative expenses decreased year over year primarily due to reduced headcount at hospice branch locations resulting from implementation of the case management staffing model.
GUIDANCE
The Company is providing full-year 2024 guidance as follows:
![Enhabit Reports Fourth Quarter Results and Issues Full-Year 2024 Guidance (4) Enhabit Reports Fourth Quarter Results and Issues Full-Year 2024 Guidance (4)](https://i0.wp.com/www.ehab.com/wp-content/uploads/2024/03/Screenshot-2024-03-06-at-3.34.28-PM-1024x112.png)
For additional considerations regarding the Company’s 2024 guidance ranges, see the supplemental information posted on the Company’s website at http://investors.ehab.com.
CONFERENCE CALL INFORMATION
The Company will host an investor conference call at 10 a.m. EST on March 7, 2024, to discuss its results for the fourth quarter of 2023. To access the live call by phone, dial toll-free (888) 660-6150 or international (929) 203-0843; the conference ID is 5248158. A simultaneous webcast of the call, along with supplemental information, may be accessed by visiting https://events.q4inc.com/attendee/272381846. Following the call, a replay will be available at Enhabit’s investor website.
ABOUT ENHABIT HOME HEALTH & HOSPICE
Enhabit Home Health & Hospice (Enhabit, Inc.) is a leading national home health and hospice provider working to expand what’s possible for patient care in the home. Enhabit’s team of clinicians supports patients and their families where they are most comfortable, with a nationwide footprint spanning 255 home health locations and 110 hospice locations across 34 states. Enhabit leverages advanced technology and compassionate teams to deliver extraordinary patient care. For more information, visit ehab.com.
OTHER INFORMATION
Note regarding presentation and reconciliation of non-GAAP financial measures
The financial data contained in this press release and supplemental information includes non-GAAP (generally accepted accounting principles (GAAP)) financial measures as defined in Regulation G under the Securities Exchange Act of 1934, including Adjusted EBITDA, Adjusted EBITDA margin, Adjusted EPS, and Adjusted free cash flow. See “Reconciliations of Non-GAAP Financial Measures” for reconciliations of the non-GAAP financial measures to the most directly comparable financial measures calculated and presented in accordance with GAAP. Such non-GAAP financial measures exclude significant components in understanding and assessing financial performance and should therefore not be considered superior to, as a substitute for or alternative to the GAAP financial measures presented in this press release. The non-GAAP financial measures in the press release may differ from similar measures used by other companies.
The Company is unable to reconcile the guidance for Adjusted EBITDA and Adjusted EPS to their corresponding GAAP measures without unreasonable effort due to the inherent difficulty in predicting, with reasonable certainty, the future impact of items that are outside the control of the Company or otherwise non-indicative of its ongoing operating performance. Accordingly, the Company relies on the exception provided by Item 10(e)(1)(i)(B) of Regulation S-K. Such items include, but are not limited to, gains or losses related to hedging instruments; loss on early extinguishment of debt; adjustments to its income tax provision (such as valuation allowance adjustments and settlements of income tax claims); and items related to corporate and facility restructurings. For the same reasons, the Company is unable to address the probable significance of the unavailable information.
Note regarding presentation of same-store comparisons
The Company uses “same-store” comparisons to explain the changes in certain performance metrics and line items within its financial statements. Same-store comparisons are calculated based on home health and hospice locations open throughout both the full current period and the immediately prior period presented. These comparisons include the financial results of market consolidation transactions in existing markets, as it is difficult to determine, with precision, the incremental impact of these transactions on the Company’s results of operations.
![Enhabit Reports Fourth Quarter Results and Issues Full-Year 2024 Guidance (5) Enhabit Reports Fourth Quarter Results and Issues Full-Year 2024 Guidance (5)](https://i0.wp.com/www.ehab.com/wp-content/uploads/2024/03/Screenshot-2024-03-06-at-3.40.55-PM-1024x774.png)
![Enhabit Reports Fourth Quarter Results and Issues Full-Year 2024 Guidance (6) Enhabit Reports Fourth Quarter Results and Issues Full-Year 2024 Guidance (6)](https://i0.wp.com/www.ehab.com/wp-content/uploads/2024/03/Screenshot-2024-03-06-at-3.41.16-PM-998x1024.png)
![Enhabit Reports Fourth Quarter Results and Issues Full-Year 2024 Guidance (7) Enhabit Reports Fourth Quarter Results and Issues Full-Year 2024 Guidance (7)](https://i0.wp.com/www.ehab.com/wp-content/uploads/2024/03/Screenshot-2024-03-06-at-3.45.55-PM-948x1024.png)
![Enhabit Reports Fourth Quarter Results and Issues Full-Year 2024 Guidance (8) Enhabit Reports Fourth Quarter Results and Issues Full-Year 2024 Guidance (8)](https://i0.wp.com/www.ehab.com/wp-content/uploads/2024/03/Screenshot-2024-03-06-at-3.49.08-PM-1024x548.png)
![Enhabit Reports Fourth Quarter Results and Issues Full-Year 2024 Guidance (9) Enhabit Reports Fourth Quarter Results and Issues Full-Year 2024 Guidance (9)](https://i0.wp.com/www.ehab.com/wp-content/uploads/2024/03/Screenshot-2024-03-06-at-3.49.49-PM-1024x656.png)
(1) Reconciliation to GAAP provided below.
(2) Unusual or nonrecurring items in Q4 2023 include costs associated with nonroutine litigation, the strategic review process and restructuring activities.
(3) Income tax adjustments include revisions to the estimates of tax balances as of the Separation date and the effect of permanent book-tax differences attributable to stock-based compensation.
(4) Diluted EPS may not sum due to rounding.
![Enhabit Reports Fourth Quarter Results and Issues Full-Year 2024 Guidance (10) Enhabit Reports Fourth Quarter Results and Issues Full-Year 2024 Guidance (10)](https://i0.wp.com/www.ehab.com/wp-content/uploads/2024/03/Screenshot-2024-03-06-at-3.50.59-PM-1024x898.png)
![Enhabit Reports Fourth Quarter Results and Issues Full-Year 2024 Guidance (11) Enhabit Reports Fourth Quarter Results and Issues Full-Year 2024 Guidance (11)](https://i0.wp.com/www.ehab.com/wp-content/uploads/2024/03/Screenshot-2024-03-06-at-3.56.46-PM-1024x899.png)
![Enhabit Reports Fourth Quarter Results and Issues Full-Year 2024 Guidance (12) Enhabit Reports Fourth Quarter Results and Issues Full-Year 2024 Guidance (12)](https://i0.wp.com/www.ehab.com/wp-content/uploads/2024/03/Screenshot-2024-03-06-at-4.03.55-PM-1024x905.png)
![Enhabit Reports Fourth Quarter Results and Issues Full-Year 2024 Guidance (13) Enhabit Reports Fourth Quarter Results and Issues Full-Year 2024 Guidance (13)](https://i0.wp.com/www.ehab.com/wp-content/uploads/2024/03/Screenshot-2024-03-06-at-4.04.29-PM-863x1024.png)
![Enhabit Reports Fourth Quarter Results and Issues Full-Year 2024 Guidance (14) Enhabit Reports Fourth Quarter Results and Issues Full-Year 2024 Guidance (14)](https://i0.wp.com/www.ehab.com/wp-content/uploads/2024/03/Screenshot-2024-03-06-at-4.05.23-PM-1024x550.png)
![Enhabit Reports Fourth Quarter Results and Issues Full-Year 2024 Guidance (15) Enhabit Reports Fourth Quarter Results and Issues Full-Year 2024 Guidance (15)](https://i0.wp.com/www.ehab.com/wp-content/uploads/2024/03/Screenshot-2024-03-06-at-4.07.19-PM-1024x491.png)
FORWARD-LOOKING STATEMENTS
Statements contained in this press release which are not historical facts, such as those relating to future events, projections, financial guidance, legislative or regulatory developments, strategy or growth opportunities, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All such estimates, projections, and forward-looking information speak only as of the date hereof, and Enhabit undertakes no duty to publicly update or revise such forward-looking information, whether as a result of new information, future events, or otherwise. Such forward-looking statements are necessarily estimates based upon current information and involve a number of risks and uncertainties, many of which are beyond our control. Actual events or results may differ materially from those anticipated in these forward-looking statements as a result of a variety of factors. While it is impossible to identify all such factors, factors which could cause actual events or results to differ materially from those estimated by Enhabit include, but are not limited to, our ability to execute on our strategic plans; regulatory and other developments impacting the markets for our services; changes in reimbursem*nt rates; general economic conditions; changes in the episodic versus non-episodic mix of our payors, the case mix of our patients, and payment methodologies; our ability to attract and retain key management personnel and healthcare professionals; potential disruptions or breaches of our or our vendors’, payors’, and other contract counterparties’ information systems; the outcome of litigation; our ability to successfully complete and integrate de novo locations, acquisitions, investments, and joint ventures; our ability to successfully integrate technology in our operations; our ability to control costs, particularly labor and employee benefit costs; and factors that affect the timing and options in our strategic review and, following our strategic review, consummating a strategic transaction on attractive terms or at all. Additional information regarding risks and factors that could cause actual results to differ materially from those expressed or implied by any forward-looking statement in this press release are described in reports filed with the SEC, including our annual report on Form 10-K and subsequent quarterly reports on Form 10-Q, copies of which are available on the Company’s website at http://investors.ehab.com.
CONTACTS
Investor Relations Contact
Crissy Carlisle [emailprotected] 469-860-6061
Media Contact
Erin Volbeda [emailprotected] 972-338-5141
- Category:Press Release, Press Room